by Valentine Chervonenko | Mar 11, 2026 | Uncategorized
Bias in pharmaceutical market research: when it’s a benefit and when it’s a threat By DOCREPLAY.ai ABSTRACT Bias is a misunderstood variable in pharmaceutical market research. The industry treats it as universally negative, something to eliminate at every turn. But...
by Valentine Chervonenko | Mar 11, 2026 | Uncategorized
Do more. Spend less.Why cost efficiency in pharmaceutical market research is a brand imperative, not a budget conversation. By DOCREPLAY.ai ABSTRACT “Waste of resources is a mortal sin.” Ingvar Kamprad built IKEA on this principle, and it made him one of the most...
by Valentine Chervonenko | Mar 11, 2026 | Uncategorized
Human-led vs. AI voice capture pharmaceutical research: A strategic framework for choosing the right methodology for the right problem. By DOCREPLAY.ai ABSTRACT Pharmaceutical brand teams face a critical choice when designing market research: humanled or AI...
by Valentine Chervonenko | Mar 11, 2026 | Uncategorized
Beyond the summary:Why quantifying verbatim responses unlocks strategic advantage in pharmaceutical research. By DOCREPLAY.ai ABSTRACT Not all qualitative research questions are the same, and not all analytical report approaches should be. Summarization is a powerful...
by Valentine Chervonenko | Mar 11, 2026 | Uncategorized
The evolution of pharmaceuticalqualitative research: what insightsleaders are prioritizing in 2026 By DOCREPLAY.ai ABSTRACT The pharmaceutical industry’s approach to qualitative market research is at an inflection point. Recent conversations with insights...
by Valentine Chervonenko | Mar 11, 2026 | Uncategorized
The 30-respondent pharmaceutical research tradition: understanding where it shines and where it can leave you exposed. By DOCREPLAY.ai ABSTRACT Most pharmaceutical brand teams default to 30 respondents for qualitative research because it’s the industry standard...
